Abstract 4347: Preclinical evaluation of pharmacokinetic interactions among nebivolol, dasatinib and devimistat in mice
Airong Li(University of Houston), Meghana V. Trivedi(University of Houston), Fatima Dagher(University of Houston), Junghwa Park(University of Houston), Amir Mohammad Gholizadeh(University of Houston), Emanuel Baltrip(University of Houston), Mikayla Skillman(University of Houston)
Cited by 1
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133